Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 102, Issue 42, Pages 15178-15183Publisher
NATL ACAD SCIENCES
DOI: 10.1073/pnas.0505539102
Keywords
lymphoma; mouse model; therapy; autoantibody; transplantation
Categories
Funding
- NCI NIH HHS [CA96547, R01 CA105001, R01 CA096547, CA81776, CA105001] Funding Source: Medline
- NIAID NIH HHS [U19 AI056363, AI56363] Funding Source: Medline
Ask authors/readers for more resources
Immunotherapy with unconjugated CD20 monoclonal antibodies has proven effective for treating non-Hodgkin's lymphoma and autoimmune disease. CD20 immunotherapy depletes mature B cells but does not effectively deplete pre-B or immature B cells, some B cell subpopulations, anti body-producing cells, or their malignant counterparts. Because CD19 is expressed earlier during B cell development, a therapeutic strategy for the treatment of early lymphoblastic leukemias/lymphomas was developed by using CD19-specific monoclonal antibodies in a transgenic mouse expressing human CD19. Pre-B cells and their malignant counterparts were depleted as well as antibody- and autoantibody-producing cells. These results demonstrate clinical utility for the treatment of diverse B cell malignancies, autoimmune disease, and humoral transplant rejection.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available